Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

about

Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.Regulation of Angiopoietin Signalling by Soluble Tie2 Ectodomain and Engineered Ligand Trap Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.

P2860

Q36331045-89596A95-E782-470B-8DA6-07BAB7FE709A Q38721711-C57E3D56-6770-4367-B1AC-F2B3484652A3 Q49275652-EB6C4EA0-5031-4927-91A9-33651A7B5639

P2860

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

Item

http://www.wikidata.org/entity/Q35657595

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@ast

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@en

type

Item

label

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@ast

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@en

prefLabel

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@ast

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@en

P1476

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

@en

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier.

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.

Intravitreal aflibercept for diabetic macular edema.

Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.

P2888

s40265-015-0421-y

P304

1153-1160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0421-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gillian M Keating

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26056030

http://www.w3.org/2001/XMLSchema#string

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

about

P2860

P2860

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698